Welcome to our dedicated page for ARTELO BIOSCIENCES SEC filings (Ticker: ARTL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Artelo Biosciences, Inc. filings document a clinical-stage pharmaceutical issuer with securities listed on Nasdaq and a pipeline centered on lipid-signaling modulation. Registration statements and amendments describe securities offerings, delayed or continuous offering registration mechanics, common stock, warrants, pre-funded warrants and capital-structure terms.
Artelo's Form 8-K filings record material events including Nasdaq continued-listing compliance, annual-meeting matters, private-placement activity, material agreements, and clinical or regulatory disclosures for programs such as ART27.13 and ART26.12. The filings connect formal governance and financing records with updates on the company's drug-development strategy and intellectual-property activity.
Artelo Biosciences, Inc. completed a one-for-three reverse stock split of its common stock effective March 10, 2026, cutting outstanding shares from 2,124,772 to approximately 708,323 and reducing authorized common shares from 500,000,000 to 166,666,667.
The company republished its audited financial statements, which show a 2025 net loss of $12,879 (thousands) versus $9,826 (thousands) in 2024 and a stockholders’ deficit of $1,272 (thousands) as of December 31, 2025. Cash and cash equivalents were $600 (thousands), while current liabilities were $4,044 (thousands), leading the auditor to cite substantial doubt about Artelo’s ability to continue as a going concern.
The notes describe repeated equity raises, convertible note financings and warrants to fund operations, plus a January 30, 2026 equity purchase agreement giving Artelo the right to direct up to $25 million in future common stock sales, with potential to increase by another $25 million.
Artelo Biosciences approved a 3-for-1 reverse stock split of its common stock, combining each three existing shares into one new share. The split is intended to increase the share price to improve marketability and liquidity, with trading on a split-adjusted basis starting March 10, 2026.
No fractional shares will be issued; holders otherwise entitled to a fraction will receive one whole share instead. The company expects approximately 708,258 shares of common stock to be issued and outstanding immediately after the reverse split, and all outstanding warrants and other derivatives will adjust automatically under their terms.
Artelo Biosciences, Inc. is a Nevada‑incorporated, clinical‑stage biopharmaceutical company based in Solana Beach, California, focused on therapeutics that modulate lipid‑signaling pathways, including the endocannabinoid system.
The company’s pipeline includes three main programs. ART27.13, a dual CB1/CB2 agonist in a Phase 1b/2a Cancer Appetite Recovery Study (CAReS), targets cancer‑related anorexia. In an interim Phase 2a analysis, patients titrated to 1,300 micrograms showed mean weight gain of about 6%, while placebo patients lost weight, with supportive trends in lean body mass and activity and a generally favorable safety profile.
ART26.12, a FABP5 inhibitor, completed a first‑in‑human Phase 1 single‑ascending‑dose study in healthy volunteers, showing only mild, transient adverse events and dose‑dependent, linear pharmacokinetics, supporting further development in chemotherapy‑induced peripheral neuropathy and other potential indications. ART12.11, a proprietary CBD/TMP cocrystal, has patent protection to 2038 and is being advanced preclinically for anxiety and other disorders, with nonclinical evidence of improved pharmacokinetics versus conventional CBD. Artelo holds worldwide exclusive licenses on ART27.13 and ART26.12, maintains an expanding patent estate around all three candidates, operates under extensive U.S. and international regulatory frameworks, and reported seven employees as of December 31, 2025.
Artelo Biosciences, Inc. entered an Equity Purchase Agreement with Square Gate Capital Master Fund, LLC – Series 5, giving Artelo the right, but not the obligation, to sell up to $25 million of common stock, with the option to increase this by an additional $25 million once the initial amount is used.
Artelo will issue 292,398 commitment shares, valued at $500,000 as of January 30, 2026, and cover up to $35,000 of Square Gate’s fees. Share sales are priced at 95% of the lowest VWAP or trade price in short measurement periods and are subject to a 19.99% exchange cap and a 4.99% beneficial ownership limit.
Artelo Biosciences received a favorable decision from a Nasdaq Hearing Panel granting extra time to fix its listing deficiencies. The company must demonstrate compliance with Nasdaq’s stockholders’ equity rule, which requires at least $2,500,000 of equity, by March 30, 2026.
Artelo has cured its prior failure to hold a timely annual shareholder meeting by completing its 2025 meeting on January 30, 2026. The company plans additional transactions to restore and sustain required equity levels but warns there is no assurance it will meet all Nasdaq continued listing standards.
Artelo Biosciences director Connie Matsui reported receiving a grant of stock options on January 30, 2026. The award covers 292 stock options, each with a $1.71 exercise price, giving the right to buy 292 shares of common stock. The options were granted at no cost and are held directly, with 292 derivative securities beneficially owned after the transaction. Vesting is contingent on Matsui continuing as a Service Provider, with all shares vesting on the earlier of the one-year anniversary of the January 30, 2026 vesting commencement date or the day before the next annual stockholder meeting following that date.
Artelo Biosciences, Inc. director Blayney Douglas received an award of stock options covering 292 shares of common stock at an exercise price of $1.71 per share. The options expire on January 30, 2036 and are held directly.
According to the grant terms, all 292 option shares vest in full if Douglas continues as a service provider until the earlier of the one-year anniversary of the vesting commencement date of January 30, 2026 or the day before the next annual stockholder meeting following that date. After this grant, he beneficially owns 292 derivative securities.
Artelo Biosciences director Emanuele Robert Martin received a small stock option grant. On January 30, 2026, he was awarded options to buy 292 shares of Artelo Biosciences common stock at an exercise price of $1.71 per share, expiring on January 30, 2036.
According to the terms, all 292 options vest in a single tranche, provided he continues as a service provider. Vesting occurs on the earlier of the one-year anniversary of the vesting commencement date of January 30, 2026, or the day before the next annual stockholder meeting following that date.
Artelo Biosciences director Kelly Steven received a new stock option grant. On January 30, 2026, Steven was awarded stock options to purchase 292 shares of Artelo Biosciences common stock at an exercise price of $1.71 per share, with no purchase price for the option itself.
The options vest in full if Steven continues as a service provider until the earlier of the one-year anniversary of the January 30, 2026 vesting commencement date or the day before the company’s next annual stockholder meeting after that date. After this grant, Steven beneficially owns 292 derivative securities directly.
Artelo Biosciences director Tamara A. Favorito reported a new stock option grant on Common Stock. On January 30, 2026, she was awarded stock options to purchase 292 shares at a conversion or exercise price of $1.71 per share.
All 292 options vest in full once, subject to her continuing as a service provider, on the earlier of the one-year anniversary of the January 30, 2026 vesting commencement date or the day before the next annual stockholder meeting following that date. After this grant, she beneficially owns 292 derivative securities directly.